Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NT 201 for enlarged pores and sebum production
NCT05784363Phase 1Completed
- Sponsor
- Merz
- Start
- Oct 2022
- Primary completion
- Jun 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in enlarged pores and seborrheic dermatitis (SD) comparing NT 201 with Placebo (2 arms). Primary endpoints: Change from Baseline to Week 4 in Pore Volume in the Cheek Area and Change from Baseline to Week 4 in Sebum Level in the Forehead Area. Started Oct 2022; status: completed.
02
Drugs
incobotulinumtoxinA
03
Conditions
enlarged poresseborrheic dermatitis (SD)
Beyond the preview
Go deeper on NCT05784363.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05784363.